12:10 PM EST - The Yield Growth Corp. : Announced that it's majority owned subsidiary NeonMind has filed an additional provisional patent application related to using psychedelics as medicine. The patent application covers the administration of a compound selected from the group consisting of lysergic acid diethylamide ("LSD") and d-lysergic acid amide ("LSA") (and compounds with similar molecular structure)in combination with an 5-HT2A antagonist to treat compulsive eating disorder, obesity and related illnesses. "Our research with our scientific team into using psilocybin to treat compulsive eating and food cravings has led to paths of inquiry for research into expanded medical uses of psychedelics," says Penny White, NeonMind CEO, "We are excited to lay the groundwork for new areas of potential research for the future." The Yield Growth Corp.
shares C.BOSS are trading unchanged at $0.14.
